A phenotypic characterisation of leukocytes processed with a prototype inertial focusing microfluidic device

The manufacturing of cellular therapies is a complex process frequently requiring manipulation of cells, buffer exchange and volume reduction. Current manufacturing processes rely on either open, low throughput centrifugation-based devices, or expensive alternatives. Inertial focusing (IF) microfluidic devices can be high-throughput, cheap and integrated into a closed system, but as yet, no IF devices have been approved for use in cellular therapy manufacturing. In this study, we investigated the suitability and capacity of our prototype IF device to process different cell types and perform medium exchange. During this seminar we will review downstream post-processing impacts on cell health, assessed using multi-parameter flow cytometry to track cell viability, functional changes, and cell fate.